A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma

Abstract

A glycolysis-based three-gene signature could serve as a novel biomarker in predicting the prognosis of patients with LUSC and it also provides additional gene targets that can be used to cure LUSC patients.